The last few weeks have seen a heated debate on Seeking Alpha and Twitter regarding the prospects of Exact Sciences' (NASDAQ:EXAS) Cologuard, once the seemingly inevitable FDA approval comes June 6th. Looking at the Bull vs. Bear argument in the market, I found myself initially inclined to be skeptical of the prospects for a test that was cutting the market by a 3rd (once every 3 years vs. annual) and 20 times the cost of the current standard of care. My experiences with the BRCA test and Sequenom's (NASDAQ:SQNM) Maternit21 launch left me generally bearish on a diagnostic launch.
However, a long time ago, I learned that one can't rely on which argument made by other...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|